Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-positive Breast Cancer|Recurrent Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: fulvestrant|DRUG: tipifarnib
Sponsor: National Cancer Institute (NCI)